住院对社区痴呆患者问题性用药的影响
结果显示问题性用药有小幅增加但无统计学显著性(调整均值1.28 vs 1.40,差值0.12,95%CI -0.03至0.26,p=0.12)。
要点
- 住院后4个月问题性用药较基线小幅增加但无统计学显著性。
- 各药物类别和多数亚组结果一致,无显著差异。
- 住院前慢性用药少于5种者出院后问题性用药增加更明显。
核心结论
- 住院对社区痴呆患者长期问题性用药有小幅、非统计学显著的影响。
- 住院前慢性用药较少者出院后问题性用药增加更明显,交互作用有统计学意义。
研究设计与样本
- 基于健康与退休研究(HRS)的队列分析,纳入2008至2018年间有住院记录的社区痴呆患者504名。
- 比较住院前4周(基线)与出院后4个月的问题性用药,使用广义线性混合模型(泊松分布)调整年龄、性别、合并症数量、住院前慢性用药和时间点。
主要发现
- 504名患者中位年龄84岁(IQR 79-90),66%女性,17%黑人。
- 问题性用药从基线到出院后调整均值1.28 vs 1.40,差值0.12(95%CI -0.03至0.26),p=0.12。
关键数值与推荐
- 问题性用药定义为:对认知有负面影响的药物(强抗胆碱能药/镇静催眠药)、2019年Beers标准药物、STOPP-V2标准药物。
- 主要比较住院前4周与出院后4个月的问题性用药数量变化。
临床怎么用
- 对社区痴呆患者住院后应关注问题性用药,尤其住院前慢性用药较少者可能增加更明显。
- 出院后4个月内可考虑系统评估问题性用药,参考Beers或STOPP-V2标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hospitalizations are frequently disruptive for persons with dementia (PWD) in part due to the use of potentially problematic medications for complications such as delirium, pain, and insomnia. We sought to determine the impact of hospitalizations on problematic medication prescribing in the months following hospitalization. METHODS: We included community-dwelling PWD in the Health and Retirement Study aged ≥66 with a hospitalization from 2008 to 2018. We characterized problematic medications as medications that negatively affect cognition (strongly anticholinergics/sedative-hypnotics), medications from the 2019 Beers criteria, and medications from STOPP-V2. To capture durable changes, we compared problematic medications 4 weeks prehospitalization (baseline) to 4 months posthospitalization period. We used a generalized linear mixed model with Poisson distribution adjusting for age, sex, comorbidity count, prehospital chronic medications, and timepoint. RESULTS: Among 1 475 PWD, 504 had a qualifying hospitalization (median age 84 (IQR = 79-90), 66% female, 17% Black). There was a small increase in problematic medications from the baseline to posthospitalization timepoint that did not reach statistical significance (adjusted mean 1.28 vs 1.40, difference 0.12 (95% CI -0.03, 0.26), p = .12). Results were consistent across medication domains and certain subgroups. In one prespecified subgroup, individuals on <5 prehospital chronic medications showed a greater increase in posthospital problematic medications compared with those on ≥5 medications (p = .04 for interaction, mean increase from baseline to posthospitalization of 0.25 for those with <5 medications (95% CI 0.05, 0.44) vs. 0.06 (95% CI -0.12, 0.25) for those with ≥5 medications). CONCLUSIONS: Hospitalizations had a small, nonstatistically significant effect on longer-term problematic medication use among PWD.
引用
- Deardorff WJ, Jing B, Growdon ME, et al. Impact of Hospitalizations on Problematic Medication Use Among Community-Dwelling Persons With Dementia. J Gerontol A Biol Sci Med Sci. 2024. PMID: 39155601. doi:10.1093/gerona/glae207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。